Document 0499
 DOCN  M9490499
 TI    Virucidal effect of myeloperoxidase on human immunodeficiency virus type
       1-infected T cells.
 DT    9411
 AU    Chochola J; Yamaguchi Y; Moguilevsky N; Bollen A; Strosberg AD;
       Stanislawski M; Laboratoire d'Immunologie, Institut de Recherches
       Scientifiques; sur le Cancer, Villejuif, France.
 SO    Antimicrob Agents Chemother. 1994 May;38(5):969-72. Unique Identifier :
       AIDSLINE MED/94346849
 AB    Myeloperoxidase is virucidal to human immunodeficiency virus type 1
       (HIV-1) in the persistently infected CEM human T-cell line or in acutely
       infected human peripheral blood mononuclear cells, as judged by viral
       infectivity and P24 radioimmunoassay. HIV-1 was specifically inactivated
       by low doses of the human myeloperoxidase (1.4 to 14.3 mU/ml) and the
       cells were spared. A higher enzyme concentration (143 mU/m) was
       cytotoxic, but uninfected CEM cells and normal lymphocytes were
       resistant to > or = 143 mU of myeloperoxidase per ml. The enzyme was
       virucidal with the Cl- present in medium and did not require exogenous
       H2O2. Catalase, an antioxidant enzyme, partially inhibited the virucidal
       effect of myeloperoxidase. Hence, the H2O2 probably came from the
       HIV-infected cells themselves. These in vitro findings indicate that the
       myeloperoxidase system is capable of inactivating HIV-1 of infected
       cells.
 DE    Antiviral Agents/*PHARMACOLOGY  Catalase/PHARMACOLOGY  Cell Line
       Glucose Oxidase/PHARMACOLOGY  Human  HIV Core Protein
       p24/IMMUNOLOGY/METABOLISM  HIV-1/*DRUG EFFECTS/METABOLISM
       Lactoperoxidase/PHARMACOLOGY  Peroxidase/*PHARMACOLOGY
       Phytohemagglutinins/PHARMACOLOGY  Radioimmunoassay  Support, Non-U.S.
       Gov't  T-Lymphocytes/DRUG EFFECTS/*MICROBIOLOGY  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).